Form 4: Calidi Biotherapeutics CEO Acquires Shares in Lieu of Cash Payment
SEC Form 4
Calidi Biotherapeutics CEO Allan Camaisa acquired 70,155 shares of common stock in lieu of cash repayments for payables owed to him.
Summary
- On September 26, 2024, Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics, Inc., acquired 70,155 shares of the company's common stock.
- The shares were issued in lieu of cash repayments for payables owed to Mr. Camaisa.
- The price per share was $1.15, which was the closing price of the issuer's common stock immediately prior to the issuance date.
- Following the transaction, Mr. Camaisa directly owns 76,712 shares of common stock.
- This does not include shares issuable upon exercise of options and warrants held by Mr. Camaisa, AJC Capital, LLC (of which Mr. Camaisa is the sole managing member and owner), and Jamir Trust (of which Mr. Camaisa is the sole trustee).
Sentiment
Score: 6
Explanation: Neutral sentiment. The transaction itself is neither overtly positive nor negative. It reflects a compensation arrangement.
Positives
- The CEO's acceptance of shares in lieu of cash may indicate confidence in the company's future prospects.
Negatives
- The issuance of shares in lieu of cash could dilute existing shareholders' equity.
Risks
- The document does not provide information about the company's overall financial health or future performance.
- The potential dilution of existing shareholders' equity should be considered.
Industry Context
This type of transaction, where executives receive shares in lieu of cash compensation, is not uncommon, particularly for companies that may be managing their cash flow carefully. It can align the executive's interests with those of shareholders.
Related Party Transactions
- The issuance of shares to the CEO in lieu of cash repayments is a related party transaction.
Stakeholder Impact
- Shareholders may experience dilution of their equity due to the issuance of new shares.
- The transaction could be viewed positively if it signals the CEO's confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 09/26/2024 | Date of the transaction where Allan Camaisa acquired shares. |
| 09/30/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.